The antitumour effect of γδ T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4509-4513

  Toru, Suzuki ^a   Shuji, Terao ^a   Bishnu, Acharya ^a   Michio, Naoe ^b   Shingo, Yamamoto ^a   Okamura, Haruki ^a   Gotoh, Akinobu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

T cells; Bladder carcinoma; Cancer immunotherapy; Histone deacetylase inhibitor; NKG2D ligands; Valproic acid

Indexed keywords

MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; VALPROIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; GABA AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS; VALPROIC ACID;

EID: 78650245512     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jones SJ and Campbell SC: Non-muscle invasive bladder cancer, In: Campbell-Walsh Urology, 8th ed. Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ (ed.): New York, Saunders, pp. 2447-2467, 2006.
2. Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T and Takahashi H: A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother 58: 1245-1255, 2009.
3. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
4. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, Habuchi T, Maekawa T and Kimura S: Intravesical administration of γδ T-cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58: 493-502, 2008.
5. Beetz S, Wesch D, Manschen L, Weite S, Oberg HH and Kabelitz D: Innate immune functions of human gammadelta T-cells. Immunobiology 213: 173-182, 2008.
6. Stresing V, Daubiné F, Benzaid I, Mönkkönen H and Clézardin P: Bisphosphonates in cancer therapy. Cancer Lett 16: 16-35, 2007.
7. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H and Maekawa T: Cytotoxic effects of γδ T-cells expanded ex vivo by a third-generation bisphosphonate for cancer immunotherapy. Int J Cancer 116: 94-99, 2005.
8. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinte A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005.
9. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate up-regulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
10. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M and Hayday AC: Targeting human γδ T-cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457, 2007.
11. Sicard H, Ingoure S, Luciani B, Serraz C, Fournié JJ, Bonneville M, Tiollier J and Romagné F: In vivo immunomanipulation of V gamma 9V delta 2 T-cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175: 5471-5480, 2005.
12. Viey E, Laplace C and Escudier B: Peripheral γδ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 5: 973-986, 2005.
13. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N and Toma H: Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T-cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56: 469-476, 2007.
14. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J and Négrier S: Phase-I study of Innacell γδTM, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57: 1599-1609, 2008.
15. Mattarollo SR, Kenna T, Nieda M and Nicol AJ: Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T-cell cytotoxicity. Cancer Immunol Immunother 56: 1285-1297, 2007.
16. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, Moriyasu F, Nieda M and Nicol AJ: Vγ9Vδ2 T-Cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int J Cancer 122: 2526-2534, 2008.
17. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D and Wesch D: Lysis of a broad range of epithelial tumour cells by human γδ T-cells: involvement of NKG2D ligands and T-cell receptor versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328, 2007.
18. Andresen L, Jensen H, Pedersen MT, Hansen KA and Skov S: Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T-cells. J Immunol 179: 8235-8242, 2007.
19. Märten A, von Lilienfeld-Toal M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T-cell cytotoxicity. Int J Cancer 119: 2359-2365, 2006.
20. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568, 2004.